Ginkgo Bioworks Holdings Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while iShares 0 3 Month Treasury Bond ETF trades at $100.53. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | SGOV | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Fixed Income |
52-Week High | $16.14 | $100.74 |
52-Week Low | $5.48 | $100.28 |
Enterprise Value | $627.78M | — |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% on the day. The technical outlook is bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights strong inflows into cash ETFs amid market volatility and Federal Reserve uncertainty. The fund offers a low-risk haven with a 0.09% expense ratio and yields around 3.54–3.65%, attracting income-focused investors.
The outlook for SGOV is stable, providing a secure parking spot for cash with minimal interest rate risk due to its short duration. Investment opportunity lies in capital preservation and competitive yield versus savings accounts. Primary risks include potential Fed rate cuts reducing yields and high investor concentration in cash-like assets if equity markets rally. The fund suits conservative portfolios seeking liquidity and safety.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →